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A B S T R A C T
Purpose: Guidelines for women with epilepsy (WWE) are advising those on enzyme inducing drugs
EIAEDs to take vitamin K the last month of pregnancy. The primary aim of this study was to investigate
whether WWE have a higher frequency of large post partum hemorrhage. Secondary we wanted to see if
this was more severe in women taking EIAEDs, and also to evaluate whether those receiving prenatal
vitamin K supplementation have a less pronounced risk.
Methods: All patients (n = 109), with the diagnosis of epilepsy giving birth at OUS Rikshospitalet from
2006 to 2011 were selected to be in the epilepsy group. They were compared to controls with regard to
the amount of post partum hemorrhage, gestational age for the mother, birth weight and APGAR score in
the newborns.
Results: No signiﬁcant difference between the groups regarding post partum hemorrhage, gestational
age, birthweight or APGAR score in the newborn was found. Also, comparing the WWE using EIAED who
received prenatal vitamin K with those who did not receive vitamin K, no signiﬁcant difference in post
partum hemorrhage could be demonstrated.
Conclusion: In this study, WWE was not found to have increased risk of post partum hemmorrhage
including those using EIAED with/without vitamin K supplementation.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Women with epilepsy (WWE) are faced with particular
challenges related to pregnancy and delivery. EIAEDs have been
thought to have a negative effect on the synthesis of vitamin K and
vitamin K dependent coagulation factors in the liver, in particular
in the fetus. Guidelines for women with epilepsy have subse-
quently advised those using EIAEDs to take vitamin K the last
month of pregnancy In addition, it is customary to give the
newborn an intramuscular injection of vitamin K.
The association between bleedings in the newborn and the use
of EIAEDs was ﬁrst mentioned in some case studies [1,2]. Crossing
of the EIAED over the placenta causing increased degeneration of
vitamin K in the fetus has been thought to be the cause
[3]. However, no epidemiological studies were done until Kaaja* Corresponding author at: Department of Neurology, Oslo University Hospital–
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bleeding complication was found in ﬁve (0.7%) of the newborn of
mothers using EIAEDs and in ﬁve (0.4%) control subjects. Bleeding
was associated with birth <32 weeks of gestation and alcohol
abuse but not with EIAEDs. This was followed by a retrospective
cohort study showing no increase of bleedings in infants of
mothers on EIAEDs, even though no vitamin K supplementation
was taken by all but 1 of the 169 mothers [5].
In 2009 The American Academy of Neurology updated their
guidelines [6] after an evaluation of all evidence based literature
1985–2007. They concluded that there is inadequate evidence to
determine if the newborns of WWE taking AEDs have a
substantially increased risk of hemorrhagic complications.
The aim of this study was to study whether there was a
difference in the occurrence of post-partum bleedings between
WWE and healthy women. Further, whether a difference could be
detected between those taking EIAEDs and the women either
taking no AED or non-EIAED. Finally we also registered complica-
tions concerning the newborn, in particular bleedings related to
birth and the neonatal period.served.
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The epilepsy group consisted of all patients (n = 109), with the
diagnosis of epilepsy giving birth at OUS Rikshospitalet from
2006 to 2011. One control for each of the WWE was chosen based
on age (5 years for all but 4 controls), time of delivery and delivery
method, resulting in a total of 218 subjects in the study. All
information was gathered from delivery charts and patient charts at
Oslo University Hospital. The groups were compared with regard to
the amount of post partum hemorrhage, gestational age, complica-
tions related to pregnancy and birth, and also to the birth weight,
APGAR score and complications in the newborns. Epilepsy medication
was divided into two groups, EIAEDs and non-EIAEDs. Further, it was
registered whether the mother had received vitamin K profylaxis the
last 4 weeks before birth. Mean and standard deviations were
calculated for all analyses. The student T test was used for
comparisons of the groups. Statistical analyses were performed using
SPSS.
3. Results
3.1. Postpartum bleedings
Mean amount of post partum bleeding for the whole study
population was 432 ml. Only three patients had bleedings over
1000 ml (1000, 1700 and 2150 ml), 2 of the 3 was epilepsy patients.
With this exception, the amount of bleeding was approximately
normally distributed.
3.2. The epilepsy groups and the control group
Mean amount of bleeding in the epilepsy group was 438 ml (SD
232). This was not signiﬁcantly different (p = 0.67) from the control
group who had a mean amount of bleeding of 426 ml (SD 189)
(Table 1).
By comparing the control group with those using EIAEDs whose
amount of bleeding was 431 ml (SD 154), no differences were
found (p = 0.54). The controls were also compared with the non-
EIAED group (mean post partum bleeding 449 ml, SD 295) and no
difference was found here either (p = 0.50). Finally, the control
group was compared to those in the epilepsy group using vitamin K
in the pregnancy. Mean amount of bleeding in this group was
418 ml (SD 148), again no difference was found (p = 0.85).Table 1
Post partum bleeding in the control and the different epilepsy patient groups.
N= Bleeding volume,
ml (mean)
P-value
Controls 109 426
All epilepsy patients 109 438 0.67
With EIAED 66 431 0.54
With non-EIAED 43 449 0.496
All epilepsy patients taking vitamin K 20 418 0.85
Table 2
Post partum bleeding in the different epilepsy patient groups according to the use of v
N Bleeding volume,
ml (mean)
All epilepsy patients with
Vit K supplementation
20 418 All ep
supp
Epilepsy patients taking EIAED and Vit K
supplementation
19 408 Epile
no Vi
All epilepsy patients taking EIAED 66 431 All ep3.3. The epilepsy groups
The epilepsy patients taking vitamin K during pregnancy
(n = 20, mean amount of bleeding 418 ml) was further compared to
those not taking vitamin K (n = 89, mean amount of bleeding
443 ml). No differences could be demonstrated (p = 0.66). The
comparison between the EIAED group and the non-EIAED group
also did not reveal any differences (p = 0.70) (Table 2).
Finally, the difference within the group of patients on EIAEDs
either on or not on vitamin K supplementation was evaluated.
Mean amount of bleeding in the vitamin K group was 408 ml (SD
146), which was not different from those not on vitamin K (441 ml,
SD 161 ml) with a p value of 0.44.
3.4. Other outcomes
The birth weight of the children of the epilepsy patients was not
signiﬁcantly different from the mean birth weight of the study
population; 3348 and 3404 g, respectively. The mean APGAR for
the study population as a whole was 9.23. The children of the
epilepsy patients had an APGAR of 9.21 whereas the newborns of
the control groups had an APGAR of 9.24, thus no signiﬁcant
difference.
3.5. The child
The focus of this study was to evaluate complications related to
post partum bleeding in the mother. We did, however also register
complications in the child (Table 3). In the 218 newborn,
42 complications were registered, with a slight preponderance
in the epilepsy group. Two deaths occurred, both in the epilepsy
group. With regard to bleedings, 3 complications in the newborn
were registered, 2 in the epilepsy group (1 little subependymal
bleeding, 1 cerebral bleeding in a very premature child leading to
death) and 1 in the control group (1 subgaeal hematoma). Five of
the infants in the epilepsy group had major malformations (MM)
(1 analatresia, 1 patent foramen ovale, 1 situs inversus/duodenal
atresia, 1 hypoplastic left ventricle, 1 congenital cystic adenoma-
toid malformation), whereas MM was registered in 2 born to
mothers in the control group (1 transposition of the large arteries,
1 tetralogy of Fallot) (Table 3).
4. Discussion
The relation between the use of EIAEDs in the mother and the
amount of postpartum bleeding has not previously been investi-
gated. None of the different comparisons between the epilepsy
group and the control group could demonstrate any differences
regarding postpartum bleedings. 3/218 of the patients had
bleedings more than 1000 ml. With this exception, the amount
of bleeding was approximately normally distributed in the study
population as a whole, and also among the epilepsy patients and
among the controls. When the different subgroups of epilepsy
patients were compared no differences were also not found.
Especially, no difference was observed between patients on EIAEDsitamin K.
N Bleeding volume,
ml (mean)
P-value
ilepsy patients without Vit K
lementation
89 443 0,66
psy patients taking EIAED and
t K supplementation
47 441 0,44
ilepsy patients taking non-EIAED 43 449 0,70
Table 3
Complications in the newborn.
Type of complication Epilepsy group Control group
Respiratory problems 6 4
Major malformations 5 2
Bleeding 2 1
Sepsis, fever, infection 2 2
Low birth weight 1 4
Premature 4 1
Others 4 2
Death 2 0
Total 26 16
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taking vitamin K supplementation.
This is a retrospective study collecting the hospital based data.
Whether the patient has been taking vitamin K and not reported
this is therefore not controllable. Another possible source of error is
the methods for measuring the bleedings. Also, in this study
1000 ml was used as a limit for a large bleeding. In practical
obstetrics, both 800 and 1000 ml are used. In further studies a limit
of 800 ml may be more useful. In addition, one can discuss whether
the patients in a university hospital are representative. However,
the comparisons between the healthy controls and the patients
indicate that this does not represent any bias.
As mentioned in the introduction there are now both
prospective and cohort studies that cannot demonstrate any
increase of bleedings in the neonates after the mothers use of
EIAEDs. In this study three infants had bleedings; one of them born
to a mother in the epilepsy group had a serious intracerebral
bleeding resulting in death. This child however, was born after
192 days, and since prematurity in itself gives the highest risk for
internal bleedings in the newborn, is it not possible to conclude
that this was because of the mother’s epilepsy or her use of EIAEDs.
In the study population 10 women experienced premature
birth, 9 of them were epilepsy patients. Even though the number is
too small to conclude in this study, an increased incidence inpermature birth in women with epilepsy is also reported in other
studies.
5. Conclusion
Enzyme inducing drugs have been related to increased amount
of bleeding in the newborn and guidelines have recommended K
vitamin in the last month of pregnancy. This has lately been
questioned, but the relation between EIAEDs and postpartum
bleedings has not been studied previously. This study could not
demonstrate any differences between epilepsy patients and
controls, nor between those using EIAEDs and non-EIAEDs. In
addition no increased bleeding could be demonstrated in the
women on EIAEDs and not using vitamin K and those on EIAEDs
taking K vitamin. These ﬁndings along with further studies in this
ﬁeld, may contribute to an altering of the guidelines concerning
WWE and prenatal vitamin K supplementation.
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